A Phase IB, Open-Label Study Evaluating the Safety and Pharmacokinetics of Venetoclax (GDC-0199, ABT-199) in Combination With Bendamustine+Rituximab (BR) or Bendamustine+Obinutuzumab (BG) in Patients With Relapsed/Refractory or Previously Untreated Chronic Lymphocytic Leukemia
Status: Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 05 Dec 2019
Price : $35 *
At a glance
- Drugs Venetoclax (Primary) ; Bendamustine; Obinutuzumab; Rituximab
- Indications Chronic lymphocytic leukaemia
- Focus Adverse reactions
- Sponsors Genentech
- 04 Sep 2019 Planned End Date changed from 30 Mar 2019 to 31 Dec 2019.
- 05 Mar 2019 Planned End Date changed from 25 Jun 2020 to 30 Mar 2019.
- 05 Mar 2019 Planned primary completion date changed from 25 Jun 2020 to 30 Mar 2019.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History